Teva Pharmaceutical (Four Oncology R&D Assets) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Teva Pharmaceutical (Four Oncology R&D Assets) General Information
Description
Four oncology development programs of Teva Pharmaceutical Industries. The business assets are CEP-32496, a potent small molecule inhibitor of BRAF, EGFR and RET, CEP-40783, a potent, highly selective, pseudo-irreversible inhibitor of AXL and cMET, CEP-40125, a nanoformulation of a modified bendamustine with potential activity in solid tumors and TEV-44229, a potent, selective inhibitor of the atypical kinase PKCiota that is in preclinical studies.
Contact Information
Corporate Office
- San Diego, CA 92121
- United States
Corporate Office
- San Diego, CA 92121
- United States
Teva Pharmaceutical (Four Oncology R&D Assets) Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Teva Pharmaceutical (Four Oncology R&D Assets) Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Teva Pharmaceutical (Four Oncology R&D Assets) FAQs
-
Where is Teva Pharmaceutical (Four Oncology R&D Assets) headquartered?
Teva Pharmaceutical (Four Oncology R&D Assets) is headquartered in San Diego, CA.
-
What industry is Teva Pharmaceutical (Four Oncology R&D Assets) in?
Teva Pharmaceutical (Four Oncology R&D Assets)’s primary industry is Buildings and Property.
-
Is Teva Pharmaceutical (Four Oncology R&D Assets) a private or public company?
Teva Pharmaceutical (Four Oncology R&D Assets) is a Private company.
-
What is the current valuation of Teva Pharmaceutical (Four Oncology R&D Assets)?
The current valuation of Teva Pharmaceutical (Four Oncology R&D Assets) is
. -
What is Teva Pharmaceutical (Four Oncology R&D Assets)’s current revenue?
The current revenue for Teva Pharmaceutical (Four Oncology R&D Assets) is
. -
Who are Teva Pharmaceutical (Four Oncology R&D Assets)’s investors?
Teva Pharmaceutical Industries has invested in Teva Pharmaceutical (Four Oncology R&D Assets).
-
When was Teva Pharmaceutical (Four Oncology R&D Assets) acquired?
Teva Pharmaceutical (Four Oncology R&D Assets) was acquired on 17-Mar-2015.
-
Who acquired Teva Pharmaceutical (Four Oncology R&D Assets)?
Teva Pharmaceutical (Four Oncology R&D Assets) was acquired by Ignyta.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »